Job Opportunity

Principal Scientist, Drug Metabolism

Location: San Diego, CA, US
Department: DMPK
Employment Type: Full Time
Reference Number: 2074512

Job Description Summary

The Clinical Pharmacology and Pre-clinical Development department at Mirati is responsible for DMPK, Toxicology, and Clinical Pharmacology. The Drug Metabolism Lead will be responsible for metabolite identification studies supporting drug discovery as well as clinical programs and will design custom ADME assays and provide MS based support to enable fast advancement of oncology drug discovery programs and profiling of leads and clinical candidates. The candidate will also work closely with project leaders on discovery programs providing DMPK support. Extensive experience within structure elucidation by LC/MS and NMR and ADME assays is required, and a strong DMPK knowledge base is desired.

Your Responsibilities:

  • Provide in vitro and in vivo drug metabolite identification for discovery leads and clinical compounds
  • Perform early metabolic soft spot analysis supporting medicinal chemistry SAR efforts
  • Develop robust LC/UV/HRMS methods supporting metabolism studies
  • Propose bio-transformation routes and determine responsible metabolic enzymes and present data to project teams
  • Collaborate with toxicologist in selection of the appropriate toxicity species
  • Design and provide MS support for non-routine in vitro ADME assays to ensure fast advancement of discovery programs and help evaluate the drug-drug interaction potential of lead compounds
  • Work closely with project leaders and provide DMPK expertise on drug discovery teams
  • Author IND reports; prepare and deliver internal presentations and external publications as driven by the project and corporate strategies

What is Required:

  • Ph.D with 10+ years, MS with 15+ years of experience in a relevant laboratory environment with natural product chemistry, analytical chemistry, DMPK and drug discovery backgroundRelevant pharmaceutical or biotech industry experience preferred
  • A proven track record of expertise in drug metabolite identification, in vitro ADME and LC/HRMS method development and trouble shooting
  • Demonstrated DMPK related experience in advancing lead compounds through preclinical discovery stages to candidate selection preferred
  • Experience with Sciex instrumentation, regulatory guidances for metabolites, and a solid understanding of fundamentals of PK and ADME preferred
  • Proteomics experience nice to have but not a must
  • Maintain effective communication with CROs supporting pre-clinical studies
  • Demonstration of outstanding communication skills through internal and external presentations and publications

About Mirati Therapeutics

Mirati Therapeutics is a late-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Mirati is using its scientific expertise to develop novel solutions in two registration-enabling programs: adagrasib (MRTX849), an investigational small molecule, potent and selective KRASG12C inhibitor, as monotherapy and in combination with other agents, and sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies. Mirati is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRASG12D inhibitor, and other oncology discovery programs. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer.

For more information about Mirati Therapeutics, visit us at or follow us on Twitter and LinkedIn. 

Why Join?

At Mirati, we have an unapologetic and relentless focus on our mission to transform the lives of patients with cancer and their loved ones. Patients and their families motivate us to work smarter, faster and better. We are driven by the knowledge that our efforts can one-day deliver life-saving therapies for the people who need us most. Urgency, open-mindedness, accountability and collaboration ground our work. These shared values are central to who we are, what we do and how we do it.

Our people fuel our success. They are fearless and passionate in their daily pursuit of our mission. We are committed to continuing to create a company and experience that attracts and keeps the best people. When you want your days to count and the work you do to matter, discovering and delivering potentially life-changing therapies is more than a job, it's the chance to be part of something bigger.

We believe diverse professional experiences and an inclusive culture can drive better outcomes for patients. We want employees to be authentic and use their perspectives to contribute to our mission in a meaningful way.

Mirati cultivates an environment where:

  • An entrepreneurial attitude is encouraged
  • Our people are empowered to speak up, embrace the gray and achieve solutions
  • Diverse experiences are an important of part making the best decisions
  • We laugh and have fun as a work family

No matter the role, we are unified by our passion for helping patients, and are inspired by a single vision - to unlock the science behind the promise of a life beyond cancer. Together, we own Mirati's success.

Learn more at

Mirati is an Equal Opportunity Employer (EOE) - we celebrate diverse experiences without regard to race, color, religion, creed, gender identity or expression, age, national origin or ancestry, citizenship, disability, sexual orientation, marital status, pregnancy, veteran status, membership in the uniformed services, genetic information, or any other basis protected by applicable law.

Notice to Third Party Agencies: Please note that Mirati Therapeutics Inc. does not accept unsolicited resumes from recruiters or employment agencies.